The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated ...

Terence Flynn, an analyst from Morgan Stanley, has initiated a new Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR). Terence ...

Novavax uses a protein-based vaccine strategy, which means people getting the vaccine receive a protein made by the virus ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants ...

The U.S. Food and Drug Administration said households are allowed to order 4 free tests. It says the new tests will detect ...

Health care providers say Iowans should get their COVID-19, influenza and RSV vaccines in September or October ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Learn about the safety and effectiveness of COVID-19 vaccines for kids, the possible side effects, and the benefits of vaccination.

Global mRNA Vaccines and Therapeutics Market is valued at approximately USD 46.8 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.5% over the forecast period ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...